ALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at Stifel Nicolaus

ALX Oncology (NASDAQ:ALXO) had its target price lowered by Stifel Nicolaus from $14.00 to $5.00 in a report released on Thursday morning, Benzinga reports. Stifel Nicolaus currently has a hold rating on the stock.

A number of other research analysts have also recently weighed in on the stock. HC Wainwright reissued a buy rating and set a $25.00 target price on shares of ALX Oncology in a research report on Thursday. Cantor Fitzgerald reaffirmed an overweight rating on shares of ALX Oncology in a report on Wednesday, May 29th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Moderate Buy and a consensus price target of $18.17.

ALX Oncology Stock Performance

Shares of NASDAQ ALXO traded down $0.19 during midday trading on Thursday, reaching $2.67. The company’s stock had a trading volume of 212,773 shares, compared to its average volume of 774,007. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.21 and a quick ratio of 5.21. The stock has a market capitalization of $139.11 million, a P/E ratio of -0.77 and a beta of 1.06. The firm has a 50 day moving average price of $7.25 and a 200-day moving average price of $11.81. ALX Oncology has a 12-month low of $2.50 and a 12-month high of $17.83.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.16. As a group, equities analysts predict that ALX Oncology will post -2.89 earnings per share for the current year.

Insider Buying and Selling

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of the stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $7.90, for a total transaction of $158,000.00. Following the transaction, the insider now directly owns 593,447 shares in the company, valued at $4,688,231.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, insider Jaume Pons sold 20,000 shares of the firm’s stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the transaction, the insider now directly owns 593,447 shares of the company’s stock, valued at $4,688,231.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sophia Randolph sold 12,000 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $15.94, for a total value of $191,280.00. Following the completion of the sale, the insider now directly owns 330,349 shares of the company’s stock, valued at approximately $5,265,763.06. The disclosure for this sale can be found here. Insiders sold 58,469 shares of company stock worth $554,946 in the last quarter. 33.40% of the stock is owned by insiders.

Institutional Trading of ALX Oncology

A number of institutional investors have recently made changes to their positions in ALXO. EntryPoint Capital LLC purchased a new position in shares of ALX Oncology in the first quarter worth $32,000. abrdn plc purchased a new position in shares of ALX Oncology in the fourth quarter valued at about $986,000. China Universal Asset Management Co. Ltd. raised its stake in shares of ALX Oncology by 445.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after acquiring an additional 4,706 shares during the last quarter. Swiss National Bank purchased a new stake in shares of ALX Oncology during the first quarter worth about $493,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology in the fourth quarter worth about $28,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.